# A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS

> **NCT06657079** · PHASE1,PHASE2 · COMPLETED · sponsor: **Damanhour University** · enrollment: 119 (actual)

## Conditions studied

- ARDS
- Prevention and Control

## Interventions

- **DRUG:** combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06657079
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2025-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06657079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06657079, "A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06657079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*